Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reata Pharmaceuticals (RETA)
NASDAQ:RETA
Holding RETA?
Track your performance easily
RETA Stock Chart & Stats
Day’s Range$172.32 - $172.46
52-Week Range― - ―
Previous Close$172.32
Volume1.99M
Average Volume (3M)N/A
Market Cap
$5.79B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$172.44Price Target Upside0.05% Upside
Rating ConsensusHold
Number of Analyst Covering9
Reata Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RETA FAQ
What was Reata Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Reata Pharmaceuticals’s market cap?
Currently, no data Available
When is Reata Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Reata Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Reata Pharmaceuticals overvalued?
According to Wall Street analysts Reata Pharmaceuticals’s price is currently Undervalued.
Does Reata Pharmaceuticals pay dividends?
Reata Pharmaceuticals does not currently pay dividends.
What is Reata Pharmaceuticals’s EPS estimate?
Reata Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Reata Pharmaceuticals have?
Currently, no data Available
What happened to Reata Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Reata Pharmaceuticals?
Among the largest hedge funds holding Reata Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Reata Pharmaceuticals’s shares valued at 68M.
---
Reata Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$172.44 (0.05% Upside)
$172.44 (0.05% Upside)
Blogger Sentiment
Bullish
RETA Sentiment 83%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Company Description
Reata Pharmaceuticals
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
---
RETA Stock 12 Month Forecast
Average Price Target
$172.44
▲(0.05% Upside)
Karyopharm Therapeutics
―
Xenon
―
Syndax Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering RETA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-49.10%
reiterated a buy rating a year ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -49.10% per trade.
---